MedTrace Logo

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

NCT04396756 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-06-03

Study results available
· View outcomes & findings →

Summary

A Phase 2a, multicenter, 4-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

Conditions

Interventions

DRUG

PLN-74809

PLN-74809

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Pliant Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Pliant Therapeutics Medical Monitor · Pliant Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-03
Primary Completion
2023-02-01
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • Italy
  • Netherlands
  • New Zealand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04396756 on ClinicalTrials.gov